Tauriga Sciences Inc. (TAUG) 0.0372 $TAUG
Tauriga Sciences Inc. Appoints Robert Millman, JD as a Member of the Company's Business Advisory Board
GlobeNewswire - Mon May 05, 9:29AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with a pending acquisition in the cannabis space, today announced the appointment of Robert Millman, JD ("Mr. Millman" to the Company's Business Advisory Board. Mr. Millman is an experienced portfolio manager focused on growth businesses in the biotechnology, specialty pharma, and medical technologies spaces. He currently serves as a Managing Director of the prestigious life sciences fund MPM Capital and is also an experienced IP ("patent" attorney. Mr. Millman is contributing his considerable individual expertise and is not representing MPM Capital in his capacity as a Business Advisory Member. Moreover, he has personally invested in Tauriga Sciences based on his confidence in their strategic plan. With this appointment of Mr. Millman, Tauriga's business advisory board is now comprised of eight highly qualified members.
Intelligent Living Builds a Diverse Cannabis Brand
ACCESSWIRE - Thu May 01, 10:24AM CDT
Whitefish, MT / May 1, 2014 / The U.S. medical cannabis market is expected to grow from $1.7 billion in 2011 to $9 billion by 2016, according to a 2011 report from See Change Strategy, while recreational legalization in Colorado and Washington could accelerate that growth. Investors have a number of different ways to gain exposure to the industry, and they may be wise to seek out the most diversified opportunities to mitigate risk in such a new business climate.
Tauriga Sciences Inc. Appoints Dr. Lawrence A. May, M.D., F.A.C.P., to the Position of Chief Medical Officer Effective Immediately
GlobeNewswire - Mon Apr 28, 7:43AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with a pending acquisition in the cannabis space, is pleased to announce that Lawrence A. May, M.D., F.A.C.P., ("Dr. May" has accepted the position of Chief Medical Officer ("CMO" . Dr. May brings a unique combination of clinical, scientific and business experience that has been developed in his over thirty year career in private practice as well as in leadership roles in both public and private companies. Prior to becoming Chief Medical Officer, Dr. May has served on Tauriga's Medical Advisory Board and has been advising the Company on developing products in the natural medicine market.
Tauriga Sciences Inc. Raises More than 1 Million in Private Placement
ACCESSWIRE - Sat Apr 26, 9:17AM CDT
Tauriga Sciences Inc.'s (OTCQB: TAUG) enjoyed strong volume Apr. 24, with 8,234,091 shares changing hands.
Tauriga Sciences Inc. Aggregate Private Placement Proceeds Exceed $1,100,000 USD Priced at 6 Cents Per Share
GlobeNewswire - Wed Apr 23, 3:38PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the "Company" , a diversified life sciences company with key assets that include active license agreements and a proprietary microbial powered fuel cell technology, has today confirmed that, in addition to the $900,000 it raised as previously disclosed in the Current Report on Form 8-K filed on April 4, 2014, the Company has raised additional capital exceeding $200,000 USD at the same terms. This private placement capital was secured at a price of 6 cents per share ("$0.06" from various institutional and accredited individual investors, which brings the total raised since March 31, 2014 to more than $1,100,00 USD all at $0.06. There were no warrants or registration rights offered in conjunction with this private placement financing and the shares issued are "restricted securities" as defined by Rule 144 of the Securities Act of 1933, as amended. This additional private placement capital has strengthened the Company's balance sheet and enabled the Company to significantly reduce its outstanding convertible debt; which as of April 23, 2014 is less than $350,000 USD.
Tauriga Sciences Inc. Appoints General Ronald R. Fogleman, USAF, Retired, as a Member of the Company's Business Advisory Board
GlobeNewswire - Tue Apr 15, 5:20AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include active license agreements and a proprietary microbial fuel cell technology, today announced the appointment of General Ronald R. Fogleman, USAF, Retired, ("General Fogleman" to the Company's Business Advisory Board. General Fogleman is an internationally recognized figure in both the aerospace and defense industries with proven leadership skills and extraordinary career achievements. With this appointment of General Fogleman, Tauriga's business advisory board is now comprised of seven highly qualified members.
Tauriga Sciences Inc. Fully Repays and Retires the Convertible Note Held by Group 10 Holdings LLC for Principal Amount of $157,500 USD
GlobeNewswire - Mon Mar 31, 10:41AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include active license agreements, topical medicinal cannabis lotions, and a proprietary microbial fuel cell technology, today announced that it has fully repaid a convertible note ("the note" held by Group 10 Holdings, LLC ("Group 10 Holdings" for the principal amount of $157,500 USD. On September 30, 2013, Tauriga borrowed $157,500 USD from Group 10 while the Company was negotiating with Bacterial Robotics LLC ("Bacterial Robotics" to acquire synthetic biology pioneer Pilus Energy LLC ("Pilus Energy" . This capital infusion was crucial at that time, to provide the Company with the resources to execute the definitive merger agreement with Pilus Energy in late November 2013. The signing of that definitive agreement and the subsequent completion of the Pilus Energy acquisition on January 28, 2014 were unquestionably the catalysts that laid the foundation for future success. Including accrued interest and contractual buyout premiums, the note was fully repaid and retired for a cash payment of $225,487.36 USD. Therefore, there will be absolutely no share conversions owed to Group 10 Holdings in conjunction with this note and the corresponding debt has been removed from the Company's balance sheet.
Tauriga Sciences Inc. Completes $800,000 USD Equity Private Placement Priced at 6 Cents per Share
GlobeNewswire - Mon Mar 31, 5:22AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include active license agreements, interests in a topical medicinal cannabis company, and a proprietary microbial fuel cell technology, has today announced the completion of a $800,000 USD equity private placement at a price of 6 cents per share ("$0.06" to various accredited investors. There were no warrants or registration rights offered in conjunction with this private placement financing. The shares issued pursuant to this private placement are "restricted securities" as defined by Rule 144 of the Securities Act of 1933, as amended.
CBS Outdoor Americas Climbs on First Day of Trading; FDA Advisory Panel Recommends Approval of Exact Sciences Corporation's Cologuard
ACCESSWIRE - Sun Mar 30, 11:16PM CDT
CBS Outdoor Americas Inc. (NYSE: CBSO) - For an in-depth report on CBS Outdoor Americas Inc. follow: www.BullTrends.com/stockquote/CBSO
Tauriga Sciences Inc. Launches $1,700,000 USD Commercial Pilot Test With the EPA and the Metropolitan Sewer District of Greater Cincinnati
GlobeNewswire - Wed Mar 26, 2:02PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include license agreements and a proprietary technology platform in the nanorobotics space, has today announced that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" has commenced a five-phase, $1,700,000 USD commercial pilot test ("commercial pilot" with the Environmental Protection Agency ("EPA" , utilizing Chicago Bridge & Iron Co. (NYSE:CBI) ("CB&I" Federal Services serving as the third-party-contractor through the EPA's Test and Evaluation ("T&E" facility. This five phase commercial pilot will include significant testing of the Pilus Energy Electrogenic Bioreactor ("EBR" synthetic biology platform for generating value from wastewater. This commercial pilot is of great importance to the Company, because it represents the scale up from the benchtop (laboratory) scale to commercial (industrial) scale. The Metropolitan Sewer District of Greater Cincinnati ("MSDGR" , which is co-located with EPA's T&E facility, will host the commercial scale EBR prototype at its main treatment plant in Cincinnati.
Tauriga Sciences Inc. Fully Retires the Secured Convertible Promissory Note Held by Typenex Co-Investment, LLC for Original Principal Amount of $555,000 USD
GlobeNewswire - Mon Mar 24, 2:05AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include license agreements, topical medicinal cannabis lotions, and a proprietary technology platform in the nanorobotics space, today announced that it has fully retired a convertible note held by Typenex Co-Investment, LLC ("Typenex" for the principal amount of $555,000 USD. On June 24, 2013, the Company entered into a Securities Purchase Agreement with Typenex, for the sale of an 8% convertible promissory note (the "Note" in the principal amount of $550,000 (which included Typenex's legal expenses in the amount of $7,500 and a $50,000 original issue discount). By retiring the Note, the Company has removed the corresponding debt from its balance sheet. Additionally the Company is working diligently to repay and retire the entirety of its remaining convertible debt and will update shareholders, once this important goal is accomplished.
Tauriga Sciences Inc. Showcases Its Acquisition of Revenue Generating California Based Developer of Topical and Medicinal Cannabis Creams
GlobeNewswire - Fri Mar 21, 12:26AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include license agreements, topical medicinal cannabis lotions, and a proprietary technology platform in the nanorobotics space, is pleased to disclose to shareholders that the Company entered into the March 11, 2014 definitive merger agreement ("definitive agreement" with Oakland, California based Honeywood LLC ("Honeywood" , an affiliate of Doc Green's Healing Collective ("Doc Green's" . Honeywood, co-founded by Daniel Kosmal, Elie Green, and Ramona Rubin, is a visionary enterprise that has been researching and developing cannabis based healing products since 2010. Honeywood's main business models and industry capabilities include: the ability to manufacture medicinal Cannabis based products, the licensing of brands and delivery technologies, and the infrastructure to provide valuable laboratory services to the fast growing medicinal cannabis industry. Honeywood currently generates revenues through the development of proprietary formulations, such as Doc Green's Therapeutic Healing Cream (www.docgreens.org). Since 2009, the Doc Green's brand has been distributed to more than 100 dispensing cooperatives and collectives (http://www.docgreens.org/find) fully compliant with California State medicinal cannabis laws and regulations.
Tauriga Sciences Inc. Appoints Mr. Alan H. Vicory Jr. PE, BCEE as the Fourth Member of Company's Scientific Advisory Board
GlobeNewswire - Tue Mar 18, 8:05PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with key assets that include license agreements, topical medicinal cannabis lotions, and a proprietary technology platform in the nanorobotics space, has today announced the appointment of Mr. Alan H. Vicory Jr. PE, BCEE ("Mr. Vicory" as the fourth member of the company's scientific advisory board. Mr. Vicory currently is a principal in the Cincinnati, Ohio office of Stantec Inc. (NYSE:STN) where he is leading regulatory interface, watershed planning and water quality initiatives throughout the Southeast region of the United States. The expertise and industry contacts that Mr. Vicory brings to the table will be extremely valuable to the Company as it prepares to launch the commercial pilot tests of its proprietary microbial based fuel cell technology ("Electrogenic Bioreactor" or "EBR" . As previously mentioned, the Company expects its initial two customers to include: The Metropolitan Sewer District of Greater Cincinnati ("MSDGC" and a large international beverage company.
American Heritage International Inc. Now Selling Disposable eCigs in Over 400 Stores
ACCESSWIRE - Tue Mar 18, 8:35AM CDT
American Heritage International Inc. (OTCQB: AHII) stock volume soared Mar. 17, with 612,487 shares changing hands, more than four times its three-month average volume of 143,272 shares.
Tauriga Sciences Inc. Signs Definitive Agreement to Acquire California's Leading Manufacturer of Topical and Medicinal Cannabis Based Therapeutic Creams
GlobeNewswire - Tue Mar 11, 1:19AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" "TAUG" or "the Company" , a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the signing of a Definitive Agreement ("the definitive agreement" with California's leading manufacturer of topical medicinal cannabis products ("Cannabis Manufacturer" since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis creams ("cream" or "lotion" or "topical cannabis products" deliver the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the definitive agreement, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies.
Tauriga Sciences Inc. Executes $1,000,000 USD Term Sheet With Institutional Investor Following the Company's MOU Signed With California's Leading Manufacturer of Topical and Medicinal Cannabis Products
GlobeNewswire - Mon Mar 03, 6:42AM CST
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified company focused on generating profitable revenues through license or acquisition agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced the execution of a non-binding term sheet of up to $1,000,000 USD to fund, in part, the Company's previously announced proposed acquisition of California's leading manufacturer of topical and medicinal cannabis products ("the Cannabis Manufacturer" . The final terms between the Company and the institutional investor ("the investor" will be disclosed in a to-be-finalized binding agreement.
Tauriga Sciences Inc. Appoints Dr. Stella M. Sung as Chairman and Chief Executive Officer Effective Immediately
GlobeNewswire - Thu Feb 27, 6:45AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced that the Company's Board of Directors ("Board" has appointed Dr. Stella M. Sung ("Dr. Sung" to the positions of Chairman of the Board ("Chairman" and Chief Executive Officer ("CEO" effective immediately. Previously Dr. Sung has served as the Company's Chief Operating Officer ("COO" since April 15, 2013 and largely focused on scientific based due diligence and on developing and executing an effective business plan for the next phase of the Company's growth. Since the completion of the Pilus Energy LLC ("Pilus" acquisition on January 28, 2014, Dr. Sung has been instrumental in the Company's commercialization efforts and is currently building and expanding the management team for the Company's future. Dr. Sung replaces the outgoing CEO Mr. Seth M. Shaw ("Mr. Shaw" , who will retain the important position of Vice President of Strategic Planning moving forward. In this capacity Mr. Shaw will exclusively focus his efforts on improving the Company's access to capital markets as well as assembling roadshows at which the Company can present to a diversified group of institutional investors.
Tauriga Sciences, Inc. Presentation at WSAF Institutional Investor Conference to Take Place on Monday, March 3, 2014 at 1:35pm EST
GlobeNewswire - Mon Feb 24, 1:20PM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, has today announced that the Company's presentation at the Wall Street Analyst Forum ("WSAF" 24th Annual Institutional Investor Conference ("the Conference" will take place at 1:35pm EST on Monday, March 3, 2014. The presentation will be for a duration of 30 minutes immediately followed by a 10 minute Question and Answer ("Q & A" session. Subsequent to that, the Company will meet privately with a number of institutional investors via a 2:15pm EST break-out session.
Tauriga Sciences Inc. Signs Memorandum of Understanding to Acquire Revenue Generating California Based Manufacturer of Topical and Medicinal Cannabis Products
GlobeNewswire - Wed Feb 19, 6:52AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" "TAUG" or "the Company" , a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the execution of a Memorandum of Understanding ("MOU" or "the agreement" with the manufacturer of California's leading topical medicinal cannabis products ("Cannabis Manufacturer" since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis lotion ("cream" or "lotion" or "topical cannabis products" delivers the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the MOU, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California; revenues are generated from development and licensing of product formulation, as well as laboratory and manufacturing services for the medicinal cannabis industry. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies.
Tauriga Sciences Inc. Appoints San Francisco Based Entrepreneur Mr. Woodrow H. Levin as Member of the Company's Business Advisory Board
GlobeNewswire - Mon Feb 10, 7:02AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company" , a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the appointment of Mr. Woodrow H. Levin ("Mr. Levin" to the Company's Business Advisory Board. Mr. Levin is a successful San Francisco, California based entrepreneur with proven leadership skills and an excellent rolodex of both institutional investors and venture capital funds. With this appointment of Mr. Levin, Tauriga's business advisory board is now comprised of 6 highly qualified members.
Tauriga Sciences Inc. Appoints Robert Millman, JD as a Member of the Company's Business Advisory Board
GlobeNewswire - Mon May 05, 9:29AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with a pending acquisition in the cannabis space, today announced the appointment of Robert Millman, JD ("Mr. Millman" to the Company's Business Advisory Board. Mr. Millman is an experienced portfolio manager focused on growth businesses in the biotechnology, specialty pharma, and medical technologies spaces. He currently serves as a Managing Director of the prestigious life sciences fund MPM Capital and is also an experienced IP ("patent" attorney. Mr. Millman is contributing his considerable individual expertise and is not representing MPM Capital in his capacity as a Business Advisory Member. Moreover, he has personally invested in Tauriga Sciences based on his confidence in their strategic plan. With this appointment of Mr. Millman, Tauriga's business advisory board is now comprised of eight highly qualified members. Intelligent Living Builds a Diverse Cannabis Brand
ACCESSWIRE - Thu May 01, 10:24AM CDT
Whitefish, MT / May 1, 2014 / The U.S. medical cannabis market is expected to grow from $1.7 billion in 2011 to $9 billion by 2016, according to a 2011 report from See Change Strategy, while recreational legalization in Colorado and Washington could accelerate that growth. Investors have a number of different ways to gain exposure to the industry, and they may be wise to seek out the most diversified opportunities to mitigate risk in such a new business climate.
Tauriga Sciences Inc. Appoints Dr. Lawrence A. May, M.D., F.A.C.P., to the Position of Chief Medical Officer Effective Immediately
GlobeNewswire - Mon Apr 28, 7:43AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with a pending acquisition in the cannabis space, is pleased to announce that Lawrence A. May, M.D., F.A.C.P., ("Dr. May" has accepted the position of Chief Medical Officer ("CMO" . Dr. May brings a unique combination of clinical, scientific and business experience that has been developed in his over thirty year career in private practice as well as in leadership roles in both public and private companies. Prior to becoming Chief Medical Officer, Dr. May has served on Tauriga's Medical Advisory Board and has been advising the Company on developing products in the natural medicine market. Tauriga Sciences Inc. Raises More than 1 Million in Private Placement
ACCESSWIRE - Sat Apr 26, 9:17AM CDT
Tauriga Sciences Inc.'s (OTCQB: TAUG) enjoyed strong volume Apr. 24, with 8,234,091 shares changing hands.
Tauriga Sciences Inc. Aggregate Private Placement Proceeds Exceed $1,100,000 USD Priced at 6 Cents Per Share
GlobeNewswire - Wed Apr 23, 3:38PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the "Company"
, a diversified life sciences company with key assets that include active license agreements and a proprietary microbial powered fuel cell technology, has today confirmed that, in addition to the $900,000 it raised as previously disclosed in the Current Report on Form 8-K filed on April 4, 2014, the Company has raised additional capital exceeding $200,000 USD at the same terms. This private placement capital was secured at a price of 6 cents per share ("$0.06" from various institutional and accredited individual investors, which brings the total raised since March 31, 2014 to more than $1,100,00 USD all at $0.06. There were no warrants or registration rights offered in conjunction with this private placement financing and the shares issued are "restricted securities" as defined by Rule 144 of the Securities Act of 1933, as amended. This additional private placement capital has strengthened the Company's balance sheet and enabled the Company to significantly reduce its outstanding convertible debt; which as of April 23, 2014 is less than $350,000 USD. Tauriga Sciences Inc. Appoints General Ronald R. Fogleman, USAF, Retired, as a Member of the Company's Business Advisory Board
GlobeNewswire - Tue Apr 15, 5:20AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include active license agreements and a proprietary microbial fuel cell technology, today announced the appointment of General Ronald R. Fogleman, USAF, Retired, ("General Fogleman" to the Company's Business Advisory Board. General Fogleman is an internationally recognized figure in both the aerospace and defense industries with proven leadership skills and extraordinary career achievements. With this appointment of General Fogleman, Tauriga's business advisory board is now comprised of seven highly qualified members. Tauriga Sciences Inc. Fully Repays and Retires the Convertible Note Held by Group 10 Holdings LLC for Principal Amount of $157,500 USD
GlobeNewswire - Mon Mar 31, 10:41AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include active license agreements, topical medicinal cannabis lotions, and a proprietary microbial fuel cell technology, today announced that it has fully repaid a convertible note ("the note" held by Group 10 Holdings, LLC ("Group 10 Holdings" for the principal amount of $157,500 USD. On September 30, 2013, Tauriga borrowed $157,500 USD from Group 10 while the Company was negotiating with Bacterial Robotics LLC ("Bacterial Robotics" to acquire synthetic biology pioneer Pilus Energy LLC ("Pilus Energy" . This capital infusion was crucial at that time, to provide the Company with the resources to execute the definitive merger agreement with Pilus Energy in late November 2013. The signing of that definitive agreement and the subsequent completion of the Pilus Energy acquisition on January 28, 2014 were unquestionably the catalysts that laid the foundation for future success. Including accrued interest and contractual buyout premiums, the note was fully repaid and retired for a cash payment of $225,487.36 USD. Therefore, there will be absolutely no share conversions owed to Group 10 Holdings in conjunction with this note and the corresponding debt has been removed from the Company's balance sheet. Tauriga Sciences Inc. Completes $800,000 USD Equity Private Placement Priced at 6 Cents per Share
GlobeNewswire - Mon Mar 31, 5:22AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include active license agreements, interests in a topical medicinal cannabis company, and a proprietary microbial fuel cell technology, has today announced the completion of a $800,000 USD equity private placement at a price of 6 cents per share ("$0.06" to various accredited investors. There were no warrants or registration rights offered in conjunction with this private placement financing. The shares issued pursuant to this private placement are "restricted securities" as defined by Rule 144 of the Securities Act of 1933, as amended. CBS Outdoor Americas Climbs on First Day of Trading; FDA Advisory Panel Recommends Approval of Exact Sciences Corporation's Cologuard
ACCESSWIRE - Sun Mar 30, 11:16PM CDT
CBS Outdoor Americas Inc. (NYSE: CBSO) - For an in-depth report on CBS Outdoor Americas Inc. follow: www.BullTrends.com/stockquote/CBSO
Tauriga Sciences Inc. Launches $1,700,000 USD Commercial Pilot Test With the EPA and the Metropolitan Sewer District of Greater Cincinnati
GlobeNewswire - Wed Mar 26, 2:02PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include license agreements and a proprietary technology platform in the nanorobotics space, has today announced that its wholly owned subsidiary Pilus Energy LLC ("Pilus Energy" has commenced a five-phase, $1,700,000 USD commercial pilot test ("commercial pilot" with the Environmental Protection Agency ("EPA" , utilizing Chicago Bridge & Iron Co. (NYSE:CBI) ("CB&I" Federal Services serving as the third-party-contractor through the EPA's Test and Evaluation ("T&E" facility. This five phase commercial pilot will include significant testing of the Pilus Energy Electrogenic Bioreactor ("EBR" synthetic biology platform for generating value from wastewater. This commercial pilot is of great importance to the Company, because it represents the scale up from the benchtop (laboratory) scale to commercial (industrial) scale. The Metropolitan Sewer District of Greater Cincinnati ("MSDGR" , which is co-located with EPA's T&E facility, will host the commercial scale EBR prototype at its main treatment plant in Cincinnati. Tauriga Sciences Inc. Fully Retires the Secured Convertible Promissory Note Held by Typenex Co-Investment, LLC for Original Principal Amount of $555,000 USD
GlobeNewswire - Mon Mar 24, 2:05AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include license agreements, topical medicinal cannabis lotions, and a proprietary technology platform in the nanorobotics space, today announced that it has fully retired a convertible note held by Typenex Co-Investment, LLC ("Typenex" for the principal amount of $555,000 USD. On June 24, 2013, the Company entered into a Securities Purchase Agreement with Typenex, for the sale of an 8% convertible promissory note (the "Note" in the principal amount of $550,000 (which included Typenex's legal expenses in the amount of $7,500 and a $50,000 original issue discount). By retiring the Note, the Company has removed the corresponding debt from its balance sheet. Additionally the Company is working diligently to repay and retire the entirety of its remaining convertible debt and will update shareholders, once this important goal is accomplished. Tauriga Sciences Inc. Showcases Its Acquisition of Revenue Generating California Based Developer of Topical and Medicinal Cannabis Creams
GlobeNewswire - Fri Mar 21, 12:26AM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include license agreements, topical medicinal cannabis lotions, and a proprietary technology platform in the nanorobotics space, is pleased to disclose to shareholders that the Company entered into the March 11, 2014 definitive merger agreement ("definitive agreement" with Oakland, California based Honeywood LLC ("Honeywood" , an affiliate of Doc Green's Healing Collective ("Doc Green's" . Honeywood, co-founded by Daniel Kosmal, Elie Green, and Ramona Rubin, is a visionary enterprise that has been researching and developing cannabis based healing products since 2010. Honeywood's main business models and industry capabilities include: the ability to manufacture medicinal Cannabis based products, the licensing of brands and delivery technologies, and the infrastructure to provide valuable laboratory services to the fast growing medicinal cannabis industry. Honeywood currently generates revenues through the development of proprietary formulations, such as Doc Green's Therapeutic Healing Cream (www.docgreens.org). Since 2009, the Doc Green's brand has been distributed to more than 100 dispensing cooperatives and collectives (http://www.docgreens.org/find) fully compliant with California State medicinal cannabis laws and regulations. Tauriga Sciences Inc. Appoints Mr. Alan H. Vicory Jr. PE, BCEE as the Fourth Member of Company's Scientific Advisory Board
GlobeNewswire - Tue Mar 18, 8:05PM CDT
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with key assets that include license agreements, topical medicinal cannabis lotions, and a proprietary technology platform in the nanorobotics space, has today announced the appointment of Mr. Alan H. Vicory Jr. PE, BCEE ("Mr. Vicory" as the fourth member of the company's scientific advisory board. Mr. Vicory currently is a principal in the Cincinnati, Ohio office of Stantec Inc. (NYSE:STN) where he is leading regulatory interface, watershed planning and water quality initiatives throughout the Southeast region of the United States. The expertise and industry contacts that Mr. Vicory brings to the table will be extremely valuable to the Company as it prepares to launch the commercial pilot tests of its proprietary microbial based fuel cell technology ("Electrogenic Bioreactor" or "EBR" . As previously mentioned, the Company expects its initial two customers to include: The Metropolitan Sewer District of Greater Cincinnati ("MSDGC" and a large international beverage company. American Heritage International Inc. Now Selling Disposable eCigs in Over 400 Stores
ACCESSWIRE - Tue Mar 18, 8:35AM CDT
American Heritage International Inc. (OTCQB: AHII) stock volume soared Mar. 17, with 612,487 shares changing hands, more than four times its three-month average volume of 143,272 shares.
Tauriga Sciences Inc. Signs Definitive Agreement to Acquire California's Leading Manufacturer of Topical and Medicinal Cannabis Based Therapeutic Creams
GlobeNewswire - Tue Mar 11, 1:19AM CDT
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" "TAUG" or "the Company"
, a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the signing of a Definitive Agreement ("the definitive agreement" with California's leading manufacturer of topical medicinal cannabis products ("Cannabis Manufacturer" since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis creams ("cream" or "lotion" or "topical cannabis products" deliver the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the definitive agreement, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies. Tauriga Sciences Inc. Executes $1,000,000 USD Term Sheet With Institutional Investor Following the Company's MOU Signed With California's Leading Manufacturer of Topical and Medicinal Cannabis Products
GlobeNewswire - Mon Mar 03, 6:42AM CST
Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified company focused on generating profitable revenues through license or acquisition agreements and the development of a proprietary technology platform in the nanorobotics space, has today announced the execution of a non-binding term sheet of up to $1,000,000 USD to fund, in part, the Company's previously announced proposed acquisition of California's leading manufacturer of topical and medicinal cannabis products ("the Cannabis Manufacturer" . The final terms between the Company and the institutional investor ("the investor" will be disclosed in a to-be-finalized binding agreement. Tauriga Sciences Inc. Appoints Dr. Stella M. Sung as Chairman and Chief Executive Officer Effective Immediately
GlobeNewswire - Thu Feb 27, 6:45AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced that the Company's Board of Directors ("Board" has appointed Dr. Stella M. Sung ("Dr. Sung" to the positions of Chairman of the Board ("Chairman" and Chief Executive Officer ("CEO" effective immediately. Previously Dr. Sung has served as the Company's Chief Operating Officer ("COO" since April 15, 2013 and largely focused on scientific based due diligence and on developing and executing an effective business plan for the next phase of the Company's growth. Since the completion of the Pilus Energy LLC ("Pilus" acquisition on January 28, 2014, Dr. Sung has been instrumental in the Company's commercialization efforts and is currently building and expanding the management team for the Company's future. Dr. Sung replaces the outgoing CEO Mr. Seth M. Shaw ("Mr. Shaw" , who will retain the important position of Vice President of Strategic Planning moving forward. In this capacity Mr. Shaw will exclusively focus his efforts on improving the Company's access to capital markets as well as assembling roadshows at which the Company can present to a diversified group of institutional investors. Tauriga Sciences, Inc. Presentation at WSAF Institutional Investor Conference to Take Place on Monday, March 3, 2014 at 1:35pm EST
GlobeNewswire - Mon Feb 24, 1:20PM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, has today announced that the Company's presentation at the Wall Street Analyst Forum ("WSAF" 24th Annual Institutional Investor Conference ("the Conference" will take place at 1:35pm EST on Monday, March 3, 2014. The presentation will be for a duration of 30 minutes immediately followed by a 10 minute Question and Answer ("Q & A" session. Subsequent to that, the Company will meet privately with a number of institutional investors via a 2:15pm EST break-out session. Tauriga Sciences Inc. Signs Memorandum of Understanding to Acquire Revenue Generating California Based Manufacturer of Topical and Medicinal Cannabis Products
GlobeNewswire - Wed Feb 19, 6:52AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" "TAUG" or "the Company"
, a diversified life sciences company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the execution of a Memorandum of Understanding ("MOU" or "the agreement" with the manufacturer of California's leading topical medicinal cannabis products ("Cannabis Manufacturer" since 2009. The Cannabis Manufacturer has developed both an extensive line of medicinal cannabis products as well as delivery technologies. This unique product line of topical cannabis lotion ("cream" or "lotion" or "topical cannabis products" delivers the pain relieving and healing power of cannabis right where its applied and is quickly absorbed through the epidermis, with nearly immediate results that last for hours without psychoactive side effects. Founded in 2009 this Cannabis Manufacturer, with which Tauriga entered into the MOU, is a revenue generating company whose products can be found in more than 100 dispensaries within the State of California; revenues are generated from development and licensing of product formulation, as well as laboratory and manufacturing services for the medicinal cannabis industry. These products were originally developed to assist people with: arthritis, sore/tense muscles, back/neck pain, sports injuries, cramps, spasms, and chronic aches. The long term plan is to aggressively expand its operations to other states and file for multiple patents to protect its unique formulations and delivery technologies. Tauriga Sciences Inc. Appoints San Francisco Based Entrepreneur Mr. Woodrow H. Levin as Member of the Company's Business Advisory Board
GlobeNewswire - Mon Feb 10, 7:02AM CST
Tauriga Sciences, Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"
, a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space, today announced the appointment of Mr. Woodrow H. Levin ("Mr. Levin" to the Company's Business Advisory Board. Mr. Levin is a successful San Francisco, California based entrepreneur with proven leadership skills and an excellent rolodex of both institutional investors and venture capital funds. With this appointment of Mr. Levin, Tauriga's business advisory board is now comprised of 6 highly qualified members. 
